Rana Al-Hallaq

Rana Al-Hallaq has a wealth of experience in the biopharmaceutical industry. Rana began their career in 2015 at Pfizer, where they served in various roles, including Partner, Pfizer Ventures and Executive Director, Pfizer Worldwide Business Development, Senior Director and Partner, Pfizer Ventures, Senior Director and Principal, Pfizer Ventures, Director Business Development, and Early Candidate Clinical Lead. In 2019, they joined the Board of Directors of Autifony Therapeutics, Arkuda Therapeutics, and NY BIO. In 2020, they joined the Board of Directors of Montis Biosciences. In 2021, they joined the Board of Directors of Triplet Therapeutics, Jnana Therapeutics, ReCode Therapeutics, and Vivet Therapeutics, and became an Observer Board of Directors at Jnana Therapeutics.

Rana Al-Hallaq earned a BA in Biology from Hamilton College between 1992 and 1996. Rana then went on to pursue a PhD in Neuroscience from Georgetown University from 1997 to 2002.